Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study (Q36361289)

13 August 2017

Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study (English)

1 reference

chronic obstructive pulmonary disease

13 August 2017

0 references

0 references

1 reference

Edward Kerwin

1

1 reference

13 August 2017

Jacques Hébert

2

1 reference

13 August 2017

Nicola Gallagher

3

1 reference

13 August 2017

Carmen Martin

4

1 reference

13 August 2017

Tim Overend

5

1 reference

13 August 2017

Vijay K T Alagappan

6

1 reference

13 August 2017

Yimeng Lu

7

1 reference

13 August 2017

Donald Banerji

8

1 reference

13 August 2017

26 July 2012

1 reference

European Respiratory Journal

13 August 2017

1 reference

13 August 2017

40

1 reference

13 August 2017

5

1 reference

13 August 2017

1106-1114

1 reference

Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485572

Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485572

Changing patterns in long-acting bronchodilator trials in chronic obstructive pulmonary disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485572

Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485572

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485572

Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485572

A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485572

Definition, epidemiology and natural history of COPD.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485572

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485572

Measuring the effects of COPD on the patient

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485572

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485572

Impact of preventing exacerbations on deterioration of health status in COPD.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485572

Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485572

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485572

Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485572

The costs of exacerbations in chronic obstructive pulmonary disease (COPD).

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485572

Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485572

Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485572

Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485572

Minimal important difference of the transition dyspnoea index in a multinational clinical trial

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485572

A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485572

A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485572

Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3485572

Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey

5 December 2018

1 reference

12 December 2020

The major limitation to exercise performance in COPD is dynamic hyperinflation

1 reference

12 December 2020

Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients

1 reference

12 December 2020

Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease

1 reference

12 December 2020

10.1183/09031936.00040712

Identifiers

DOI

1 reference

13 August 2017

1 reference

13 August 2017

PubMed publication ID

23060624

1 reference